A systematic review shows bevacizumab combinations improve outcomes in platinum-resistant ovarian cancer, suggesting effective options.
Bevacizumab-based combinations demonstrate consistent benefits across multiple regimens for PROC. Paclitaxel + bevacizumab emerges as the optimal balance of efficacy and safety. Topotecan + sorafenib could be an alternative for patients who are ineligible for anti-angiogenic therapy.
No takes yet. Share an insight, caveat, or question.
Ying et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: